Freja Kirsebom
@freja-kirsebom.bsky.social
Senior epidemiologist - respiratory virus surveillance and vaccine evaluations at UK Healthy Security Agency. PhD in the immunology of respiratory viral infections.
Job opportunity at UKHSA - we are looking for 2 epidemiologists to join the respiratory virus section in the Immunisations division.
Link to apply below & happy to chat.
www.civilservicejobs.service.gov.uk/csr/index.cg...
Link to apply below & happy to chat.
www.civilservicejobs.service.gov.uk/csr/index.cg...
Senior Scientist - Civil Service Jobs - GOV.UKGOV.UK
Search and apply for jobs in the UK Civil Service
www.civilservicejobs.service.gov.uk
December 23, 2024 at 2:15 PM
Job opportunity at UKHSA - we are looking for 2 epidemiologists to join the respiratory virus section in the Immunisations division.
Link to apply below & happy to chat.
www.civilservicejobs.service.gov.uk/csr/index.cg...
Link to apply below & happy to chat.
www.civilservicejobs.service.gov.uk/csr/index.cg...
Our study on the effectiveness of the COVID-19 vaccines in preventing disease in pregnant women and their infants is now published in BMJ Medicine.
https://bmjmedicine.bmj.com/content/3/1/e000696
https://bmjmedicine.bmj.com/content/3/1/e000696
December 11, 2024 at 5:55 PM
Our study on the effectiveness of the COVID-19 vaccines in preventing disease in pregnant women and their infants is now published in BMJ Medicine.
https://bmjmedicine.bmj.com/content/3/1/e000696
https://bmjmedicine.bmj.com/content/3/1/e000696
FluSurvey is one of @UKHSA's systems for monitoring respiratory infections. It is a critical tool which helps us better understand infection and illness in the community.
Sign up to take part! https://flusurvey.net/en
(for UK residents only)
Sign up to take part! https://flusurvey.net/en
(for UK residents only)
December 11, 2024 at 5:55 PM
FluSurvey is one of @UKHSA's systems for monitoring respiratory infections. It is a critical tool which helps us better understand infection and illness in the community.
Sign up to take part! https://flusurvey.net/en
(for UK residents only)
Sign up to take part! https://flusurvey.net/en
(for UK residents only)
First real-world data on the vaccine effectiveness (VE) of the Sanofi booster now out.
TLDR; the Sanofi booster provides good protection (30-50% on top of the protection remaining from a waned autumn booster) against hospitalisation in those aged 75+.
https://www.medrxiv.org/content/10.1101/20...
TLDR; the Sanofi booster provides good protection (30-50% on top of the protection remaining from a waned autumn booster) against hospitalisation in those aged 75+.
https://www.medrxiv.org/content/10.1101/20...
December 11, 2024 at 5:55 PM
First real-world data on the vaccine effectiveness (VE) of the Sanofi booster now out.
TLDR; the Sanofi booster provides good protection (30-50% on top of the protection remaining from a waned autumn booster) against hospitalisation in those aged 75+.
https://www.medrxiv.org/content/10.1101/20...
TLDR; the Sanofi booster provides good protection (30-50% on top of the protection remaining from a waned autumn booster) against hospitalisation in those aged 75+.
https://www.medrxiv.org/content/10.1101/20...
In our latest pre-print we estimate vaccine effectiveness (VE) against hospitalisation and disease severity for BQ.1, CH.1.1. and XBB.1.5.
TLDR; vaccines provide good protection against all sub-lineages & there were no major differences in severity.
http://www.medrxiv.org/content/10.1101/20...
TLDR; vaccines provide good protection against all sub-lineages & there were no major differences in severity.
http://www.medrxiv.org/content/10.1101/20...
December 11, 2024 at 5:55 PM
In our latest pre-print we estimate vaccine effectiveness (VE) against hospitalisation and disease severity for BQ.1, CH.1.1. and XBB.1.5.
TLDR; vaccines provide good protection against all sub-lineages & there were no major differences in severity.
http://www.medrxiv.org/content/10.1101/20...
TLDR; vaccines provide good protection against all sub-lineages & there were no major differences in severity.
http://www.medrxiv.org/content/10.1101/20...
Exciting opportunity - looking for a motivated senior epidemiologist for a permanent position in my team.
Salary: £40,867-£45,998
Closes: 20 Aug 2023
Please R/T. Happy to chat with anyone looking to apply.
https://www.jobs.nhs.uk/candidate/jobadvert/K9919-23-0265
@pubhealthjobsuk @IDDjobs @P...
Salary: £40,867-£45,998
Closes: 20 Aug 2023
Please R/T. Happy to chat with anyone looking to apply.
https://www.jobs.nhs.uk/candidate/jobadvert/K9919-23-0265
@pubhealthjobsuk @IDDjobs @P...
December 11, 2024 at 5:55 PM
Exciting opportunity - looking for a motivated senior epidemiologist for a permanent position in my team.
Salary: £40,867-£45,998
Closes: 20 Aug 2023
Please R/T. Happy to chat with anyone looking to apply.
https://www.jobs.nhs.uk/candidate/jobadvert/K9919-23-0265
@pubhealthjobsuk @IDDjobs @P...
Salary: £40,867-£45,998
Closes: 20 Aug 2023
Please R/T. Happy to chat with anyone looking to apply.
https://www.jobs.nhs.uk/candidate/jobadvert/K9919-23-0265
@pubhealthjobsuk @IDDjobs @P...
Great news for RSV prevention in England!
The JCVI published their statement today recommending that an RSV immunisation programme, that is cost effective, should be developed for both infants and older adults.
https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-...
The JCVI published their statement today recommending that an RSV immunisation programme, that is cost effective, should be developed for both infants and older adults.
https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-...
December 11, 2024 at 5:55 PM
Great news for RSV prevention in England!
The JCVI published their statement today recommending that an RSV immunisation programme, that is cost effective, should be developed for both infants and older adults.
https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-...
The JCVI published their statement today recommending that an RSV immunisation programme, that is cost effective, should be developed for both infants and older adults.
https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-...
Great to present our latest work today at #ECCMID2023
December 11, 2024 at 5:55 PM
Great to present our latest work today at #ECCMID2023
Very excited to be in Copenhagen for #ECCMID23!
I’ll be speaking in Hall M tomorrow (Sunday 16th April), presenting our latest vaccine effectiveness estimates of bivalent boosters and against current variants of concern; BQ.1, CH.1.1 and XBB.1.5.
Come say hi! ☺️
I’ll be speaking in Hall M tomorrow (Sunday 16th April), presenting our latest vaccine effectiveness estimates of bivalent boosters and against current variants of concern; BQ.1, CH.1.1 and XBB.1.5.
Come say hi! ☺️
December 11, 2024 at 5:55 PM
Very excited to be in Copenhagen for #ECCMID23!
I’ll be speaking in Hall M tomorrow (Sunday 16th April), presenting our latest vaccine effectiveness estimates of bivalent boosters and against current variants of concern; BQ.1, CH.1.1 and XBB.1.5.
Come say hi! ☺️
I’ll be speaking in Hall M tomorrow (Sunday 16th April), presenting our latest vaccine effectiveness estimates of bivalent boosters and against current variants of concern; BQ.1, CH.1.1 and XBB.1.5.
Come say hi! ☺️
Now out as a pre-print - our latest data on the long term duration of protection of the monovalent COVID-19 vaccines, and vaccine effectiveness (VE) of the bivalent booster vaccines against hospitalisation in England.
https://www.medrxiv.org/content/10.1101/2023.03.31.23288018v1
https://www.medrxiv.org/content/10.1101/2023.03.31.23288018v1
December 11, 2024 at 5:55 PM
Now out as a pre-print - our latest data on the long term duration of protection of the monovalent COVID-19 vaccines, and vaccine effectiveness (VE) of the bivalent booster vaccines against hospitalisation in England.
https://www.medrxiv.org/content/10.1101/2023.03.31.23288018v1
https://www.medrxiv.org/content/10.1101/2023.03.31.23288018v1
Our paper on the effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England has been featured in the Editors' Highlights of @NatureComms ‡
https://www.nature.com/collections/jcbdhegiab
December 11, 2024 at 5:55 PM
Our paper on the effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England has been featured in the Editors' Highlights of @NatureComms ‡
https://www.nature.com/collections/jcbdhegiab
Our paper on the effectiveness of the AstraZeneca (AZ; ChAdOx1-S) vaccine when used as a booster is now peer-reviewed and out
https://www.nature.com/articles/s41467-022-35168-7.pdf
https://www.nature.com/articles/s41467-022-35168-7.pdf
December 11, 2024 at 5:55 PM
Our paper on the effectiveness of the AstraZeneca (AZ; ChAdOx1-S) vaccine when used as a booster is now peer-reviewed and out
https://www.nature.com/articles/s41467-022-35168-7.pdf
https://www.nature.com/articles/s41467-022-35168-7.pdf
Vaccine effectiveness (VE) of the bivalent booster vaccines against COVID-19 hospitalisation in England -> first data now out in the UKHSA vaccine surveillance report
1/7
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1121345/vaccine-surveilla...
1/7
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1121345/vaccine-surveilla...
December 11, 2024 at 5:55 PM
Vaccine effectiveness (VE) of the bivalent booster vaccines against COVID-19 hospitalisation in England -> first data now out in the UKHSA vaccine surveillance report
1/7
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1121345/vaccine-surveilla...
1/7
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1121345/vaccine-surveilla...
Our latest pre-print where we estimate vaccine effectiveness (VE) against hospitalisation following infection with the Omicron sub-lineages BA.4 and BA.5 in England is now up:
https://www.medrxiv.org/content/10.1101/2022.08.31.22279444v1
https://www.medrxiv.org/content/10.1101/2022.08.31.22279444v1
December 11, 2024 at 5:55 PM
Our latest pre-print where we estimate vaccine effectiveness (VE) against hospitalisation following infection with the Omicron sub-lineages BA.4 and BA.5 in England is now up:
https://www.medrxiv.org/content/10.1101/2022.08.31.22279444v1
https://www.medrxiv.org/content/10.1101/2022.08.31.22279444v1
Now peer-reviewed and published @TheLancetInfDis, our study on vaccine effectiveness (VE) against symptomatic disease and hospitalisation for BA.2 compared to BA.1.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00309-7/fulltext
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00309-7/fulltext
December 11, 2024 at 5:55 PM
Now peer-reviewed and published @TheLancetInfDis, our study on vaccine effectiveness (VE) against symptomatic disease and hospitalisation for BA.2 compared to BA.1.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00309-7/fulltext
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00309-7/fulltext
The first real-world data on the vaccine effectiveness (VE) of the AstraZeneca booster against symptomatic disease and hospitalisation with Delta and Omicron - new pre-print from us this week.
https://khub.net/documents/135939561/338928724/Effectiveness+of+ChAdOx1-S+COVID-19+booster+vaccination+...
https://khub.net/documents/135939561/338928724/Effectiveness+of+ChAdOx1-S+COVID-19+booster+vaccination+...
December 11, 2024 at 5:55 PM
The first real-world data on the vaccine effectiveness (VE) of the AstraZeneca booster against symptomatic disease and hospitalisation with Delta and Omicron - new pre-print from us this week.
https://khub.net/documents/135939561/338928724/Effectiveness+of+ChAdOx1-S+COVID-19+booster+vaccination+...
https://khub.net/documents/135939561/338928724/Effectiveness+of+ChAdOx1-S+COVID-19+booster+vaccination+...
Pre-print of our study investigating vaccine effectiveness (VE) against symptomatic disease caused by the Omicron sub-lineage BA.2 is out on medRxiv today
https://www.medrxiv.org/content/10.1101/2022.03.22.22272691v1
https://www.medrxiv.org/content/10.1101/2022.03.22.22272691v1
December 11, 2024 at 5:55 PM
Pre-print of our study investigating vaccine effectiveness (VE) against symptomatic disease caused by the Omicron sub-lineage BA.2 is out on medRxiv today
https://www.medrxiv.org/content/10.1101/2022.03.22.22272691v1
https://www.medrxiv.org/content/10.1101/2022.03.22.22272691v1
Our most comprehensive analysis so far on the protection conferred by vaccines against hospitalisation over time is published today in the UKHSA Vaccine Surveillance report
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063023/Vaccine-surveillanc...
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063023/Vaccine-surveillanc...
December 11, 2024 at 5:56 PM
Our most comprehensive analysis so far on the protection conferred by vaccines against hospitalisation over time is published today in the UKHSA Vaccine Surveillance report
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063023/Vaccine-surveillanc...
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063023/Vaccine-surveillanc...
Our peer-reviewed paper estimating vaccine effectiveness against symptomatic disease with Omicron is now out!
https://www.nejm.org/doi/full/10.1056/NEJMoa2119451?query=featured_home
https://www.nejm.org/doi/full/10.1056/NEJMoa2119451?query=featured_home
December 11, 2024 at 5:56 PM
Our peer-reviewed paper estimating vaccine effectiveness against symptomatic disease with Omicron is now out!
https://www.nejm.org/doi/full/10.1056/NEJMoa2119451?query=featured_home
https://www.nejm.org/doi/full/10.1056/NEJMoa2119451?query=featured_home
Great to see a little paper from my PhD has been selected for the @SciReports Editor's Choice Negative Results Collection.
https://www.nature.com/collections/gcifjebabg?sap-outbound-id=E5B79DC85EA936125CD326DA799BB1857D82D192&utm_source=hybris-campaign&utm_medium=email&utm_campaign=111_BADM01_00...
https://www.nature.com/collections/gcifjebabg?sap-outbound-id=E5B79DC85EA936125CD326DA799BB1857D82D192&utm_source=hybris-campaign&utm_medium=email&utm_campaign=111_BADM01_00...
December 11, 2024 at 5:56 PM
Great to see a little paper from my PhD has been selected for the @SciReports Editor's Choice Negative Results Collection.
https://www.nature.com/collections/gcifjebabg?sap-outbound-id=E5B79DC85EA936125CD326DA799BB1857D82D192&utm_source=hybris-campaign&utm_medium=email&utm_campaign=111_BADM01_00...
https://www.nature.com/collections/gcifjebabg?sap-outbound-id=E5B79DC85EA936125CD326DA799BB1857D82D192&utm_source=hybris-campaign&utm_medium=email&utm_campaign=111_BADM01_00...
Two important updates from our team this week:
- Vaccine effectiveness (VE) against symptomatic disease after Omicron BA.2 shows that VE remains unchanged
- VE against death after Omicron BA.1 shows VE is 95% at 2+ weeks after booster
1/7
Full report
https://assets.publishing.service.gov.uk/g...
- Vaccine effectiveness (VE) against symptomatic disease after Omicron BA.2 shows that VE remains unchanged
- VE against death after Omicron BA.1 shows VE is 95% at 2+ weeks after booster
1/7
Full report
https://assets.publishing.service.gov.uk/g...
December 11, 2024 at 5:56 PM
Two important updates from our team this week:
- Vaccine effectiveness (VE) against symptomatic disease after Omicron BA.2 shows that VE remains unchanged
- VE against death after Omicron BA.1 shows VE is 95% at 2+ weeks after booster
1/7
Full report
https://assets.publishing.service.gov.uk/g...
- Vaccine effectiveness (VE) against symptomatic disease after Omicron BA.2 shows that VE remains unchanged
- VE against death after Omicron BA.1 shows VE is 95% at 2+ weeks after booster
1/7
Full report
https://assets.publishing.service.gov.uk/g...
This week's updated analysis from our team on vaccine effectiveness against Omicron infection is now published in the UKHSA Technical Briefing.
Good news - protection from the boosters against severe disease continues to be well maintained.
https://assets.publishing.service.gov.uk/government/up...
Good news - protection from the boosters against severe disease continues to be well maintained.
https://assets.publishing.service.gov.uk/government/up...
December 11, 2024 at 5:56 PM
This week's updated analysis from our team on vaccine effectiveness against Omicron infection is now published in the UKHSA Technical Briefing.
Good news - protection from the boosters against severe disease continues to be well maintained.
https://assets.publishing.service.gov.uk/government/up...
Good news - protection from the boosters against severe disease continues to be well maintained.
https://assets.publishing.service.gov.uk/government/up...
This week, we were able to estimate vaccine effectiveness (VE) against hospitalisation for the first time. In short, good news. VE after a booster is close to 90%. The full update from our team is published in this week's technical briefing update:
https://assets.publishing.service.gov.uk/govern...
https://assets.publishing.service.gov.uk/govern...
December 11, 2024 at 5:56 PM
This week, we were able to estimate vaccine effectiveness (VE) against hospitalisation for the first time. In short, good news. VE after a booster is close to 90%. The full update from our team is published in this week's technical briefing update:
https://assets.publishing.service.gov.uk/govern...
https://assets.publishing.service.gov.uk/govern...
An update from our team on the latest vaccine effectiveness (VE) estimates against symptomatic infection with the Omicron variant has now been published in the UKHSA Variant Technical Briefing 33 (page 24).
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat...
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat...
December 11, 2024 at 5:56 PM
An update from our team on the latest vaccine effectiveness (VE) estimates against symptomatic infection with the Omicron variant has now been published in the UKHSA Variant Technical Briefing 33 (page 24).
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat...
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat...
Our first initial estimates of vaccine effectiveness (VE) against symptomatic disease with the Omicron variant are now out. In short, VE remains high following a Pfizer booster after AZ or Pfizer, but is reduced after two doses.
More below 👇
1/11
More below 👇
1/11
December 11, 2024 at 5:56 PM
Our first initial estimates of vaccine effectiveness (VE) against symptomatic disease with the Omicron variant are now out. In short, VE remains high following a Pfizer booster after AZ or Pfizer, but is reduced after two doses.
More below 👇
1/11
More below 👇
1/11